Results 51 to 60 of about 51,607 (296)
Daunorubicin and Cytarabine (Vyxeos)
Canadian Journal of Health Technologies, 2021 CADTH recommends that Vyxeos should be reimbursed by public drug plans for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) if certain conditions are met. Vyxeos should only be reimbursed if the induction cycles are administered in an inpatient ...
openaire +3 more sources
Türk Oftalmoloji Dergisi, 2021 We report two patients who developed toxic keratopathy following high-dose cytarabine chemotherapy and whose symptoms resolved following topical loteprednol etabonate 0.5% treatment.
Gökçen Özcan +1 more
doaj +1 more source
Pharmaceutics, 2022 Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or ...
Álvaro Pinto-Merino +7 more
doaj +1 more source
American journal of hematology/oncology, 2018 Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open‐label, phase 2 study (NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndromes (MDS ...
J. Cortes +16 more
semanticscholar +1 more source
Viridicatol from the Deep‐Sea‐Derived Fungus Alleviates Bone Loss by Targeting the Wnt/SHN3 Pathway
Advanced Science, EarlyView.Viridicatol (VDC), isolated from the deep‐sea‐derived fungus, enhances osteogenesis in vitro and in vivo by targeting Wnt/SHN3 signaling pathway. It can be delivered via engineered nanovesicles to mitigate bone loss of osteoporosis, fracture repair, and osteogenesis imperfecta.
Chun‐Lan Xie +10 more
wiley +1 more source
Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research)
Креативная хирургия и онкология, 2020 Introduction. Mantle cell lymphoma is a rare type of B-cell non-Hodgkin lymphoma. According to statistics the incidence of this disorder amounts to 2-3 per 100,000 people; this is about 6% of all non-Hodgkin lymphomas.
E. I. Kankumasheva +1 more
doaj +1 more source
Advances in Hematology, 2015 Introduction. The incidence of Acute Myeloid Leukemia (AML) increases progressively with age and its treatment is challenging. This prospective case control study was undertaken to compare the safety, efficacy, and cost-effectiveness of decitabine with ...
Linu A. Jacob +6 more
doaj +1 more source
Effects of immunoregulatory drugs on human peripheral blood T lymphocytes function in vitro [PDF]
Archive of Oncology, 2002 BACKGROUND: The purpose of the study was to evaluate the mode of action of different immunoregulatory drugs in lymphocyte proliferation and activation METHODS: The drugs studied were prednisolone (PRED), cyclosporin A (CsA) the recombination of PRED and ...
Hatzistilianou Marija +6 more
doaj +1 more source
TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, EarlyView.ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah +2 more
wiley +1 more source
Cancer Medicine, 2023 Objective We aimed to retrospectively discern the heterogeneity of outcomes from clinicopathological characteristics and next‐generation sequencing (NGS) data in adult patients with NPM1‐mutated (NPM1mut) acute myeloid leukemia (AML) induced with ...
Biao Wang +4 more
doaj +1 more source